The pharmacologic preconditioning agent RBT-1, a first-in-class drug for patients undergoing cardiothoracic surgery, reduces the incidence of anemia, blood transfusion and use of supplemental iron in these patients, according to research presented at the 2023 annual meeting of the American Society for Enhanced Recovery and Perioperative Medicine.
A combination of stannic protoporfin and iron sucrose, RBT-1 upregulates anti-inflammatory, antioxidant and iron-scavenging pathways. It was granted a